As a first-line treatment for advanced EGFR mutation-positive non-small cell lung carcinoma, Erlotinib was found to be superior to standard chemotherapy and conferred a better progression-free survival in patients [54]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.